BMC Cancer 2004, 4:63 http://www.biomedcentral.com/1471-2407/4/63 preparations at lower (presumably side effect free) doses in a clinical trial of human thyroid tumours. Competing interests (medicine) None declared. Acknowledgements This work was supported by a MIUR Cofin 2003 grant to D. Russo, a MIUR Cofin 2002 grant to M. Fresta and by a grant from Italian Ministry of Health to S. Filetti. References 1. Ain KB: Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998, 8:715-726. 2. Pasieka JL: Anaplastic thyroid cancer. Curr Opin Oncol 2003, 15:78-83. 3. Abratt RP: Gemcitabine hydrochloride: combination of activ- ity and tolerability (Summary). Anticancer Drugs 1995, 6:63-64. 4. Haller DG: Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003, 56(4 Suppl):16-23. 5. Fowler WC Jr, Van Le L: Gemcitabine as a single-agent treat- ment for ovarian cancer. Gynecol Oncol 2003, 90:S21-23. 6. Harper P: Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer. Semin Oncol 2003, 30(4 Suppl 10):2-12. 7. Lawrence TS: Radiation sensitizers and targeted therapies. Oncology (Huntingt) 2003, 17(12 Suppl 13):23-28. 8. Ringel MD, Greenberg M, Chen X, Hayre N, Suzuki K, Priebat D, Saji M, Burman KD: Cytotoxic activity of 2',2'-difluorodeoxycyti- dine (Gemcitabine) in poorly differentiated thyroid carci- noma cells. Thyroid 2000, 10:865-869. 9. Delord JP, Raymond E, Chaouche M, Ruffie P, Ducreux M, Faivre S, Boige V, Le Chevalier T, Rixe O, Baudin E, Pautier P, Rodier JM, Chouaki N, Escudier B, Kayitalire L, Armand JP: A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. Ann Oncol 2000, 11:73-79. 10. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK: Maximum-tolerated dose defined for single-agent gemcitab- ine. A phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer. J Clin Oncol 1997, 15:310-316. 11. Fresta M, Panico AM, Bucolo C, Giannavola C, Puglisi G: Character- ization and in-vivo ocular absorption of liposome-encapsu- lated acyclovir. J Pharm Pharmacol 1999, 51:565-576. 12. Fresta M, Puglisi G: Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes. Pharm Res 1999, 16:1843-1849. 13. Russo D, Arturi F, Bulotta S, Pellizzari L, Filetti S, Manzini G, Damante G, Tell G: Ape1/ref-1 expression and cellular localization in human thyroid carcinoma cell lines. J Endocrinol Invest 2001, 24:RC10-12. 14. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN: Lipo- some delivery of ciprofloxacin against intracellular Fran- cisella tularensis infection. J Control Rel 2003, 92:265-273. 15. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M: Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999, 141:443-457. 16. Spitzweg C, Morris JC: The sodium iodide symporter: its patho- physiological and therapeutic implications. Clin Endocrinol 2002, 57:559-574. 17. Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, Yamashita S, Niwa M: Adenovirus-mediated tumor suppres- sor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 2000, 85:4081-4086. 18. Takeda T, Inaba H, Yamazaki M, Kyo S, Miyamoto T, Suzuki S, Ehara T, Kakizawa T, Hara M, DeGroot LJ, Hashizume K: Tumor-specific gene therapy for undifferentiated thyroid carcinoma utiliz- ing the telomerase reverse transcriptase promoter. J Clin Endocrinol Metab 2003, 88:3531-3538. 19. To H, Ohdo S, Shin M, Uchimaru H, Yukawa E, Higuchi S, Fujimura A, Kobayashi E: Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats. J Pharm Pharmacol 2003, 55:803-810. 20. Allen TM: Liposomes. Opportunities in drug delivery. Drugs 1997, 54:8-14. 21. Gebbia V, Mauceri G, Fallica G, Borsellino N, Tirrito ML, Testa A, Varvara F, Colombo A, Ferrera P: Pegylated liposomal doxoru- bicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology 2002, 63:23-30. 22. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK: Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998, 95:4607-4612. 23. Voskoglou-Nomikos T, Pater JL, Seymour L: Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003, 9:4227-4239. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/4/63/prepub Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp BioMedcentral Page 5 of 5 (page number not for citation purposes)